Roche to Introduce ATR Inhibitor RP-3500 for $1.2 Billion
On June 1, Repare Therapeutics announced that it has entered into a global license and collaboration agreement with Roche for the development and commercialization of camonsertib (RP-3500).
Under the agreement, Roche will undertake the development of camonsertib, with the potential to expand development into other oncology and multiple combination studies. Repare will receive an upfront payment of $125 million and is eligible to receive up to $1.2 billion in potential development, regulatory, commercial and sales milestones, as well as royalties on global net product sales.
You May Interested In
2026-09-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lonza acquires Roche US biologics facility for $1.2 billion
-
Lonza acquires biologics plant from Roche for $1.2 billion
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Aβ monoclonal antibody is broken again, Alzheimer's disease new drug research and development is a long way, who can break the deadlock?
-
Roche's Next-generation C5 Complement Inhibitor Crovalimab Successfully Completed Phase III Study in China
-
Roche's TIGIT Monoclonal Antibody Collapses Again, And A Large Number of Domestic Biopharmaceutical Companies are Deployed
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
-
Roche's Potential 'First-in-class' Bispecific Therapy Wins EU CHMP Support
-
Novartis has the most new drugs approved, and Roche's new drugs have the highest value!
-
Roche's 2020 annual report is released, sales of innovative drugs surge
Recommend Reading
-
![The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time]()
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
![IMCD Opens Beauty and Personal Care Lab in California]()
IMCD Opens Beauty and Personal Care Lab in California
-
![Soybeans Tread Water Amid Trade Whispers and Biofuel Hopes]()
Soybeans Tread Water Amid Trade Whispers and Biofuel Hopes
-
![IFF to Establish Scent Creative Center in Mumbai]()
IFF to Establish Scent Creative Center in Mumbai
-
![“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”]()
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
![Bearish Factors Persist, Adipic Acid Prices in China Decline]()
Bearish Factors Persist, Adipic Acid Prices in China Decline
-
![Formic Acid Prices Stabilize After Declining Post-Holiday]()
Formic Acid Prices Stabilize After Declining Post-Holiday
-
![Cost-driven fluctuations and decline in phthalic anhydride market prices in 2025; prices may first strengthen and then stabilize in 2026]()
Cost-driven fluctuations and decline in phthalic anhydride market prices in 2025; prices may first strengthen and then stabilize in 2026
-
![Styrene-Butadiene Rubber Market Shows Weak Downward Trend]()
Styrene-Butadiene Rubber Market Shows Weak Downward Trend
-
![This Week's Styrene Market Slightly Rises (1.5-1.9) in China]()
This Week's Styrene Market Slightly Rises (1.5-1.9) in China
